NOPAIN Act Data Shows Early Adoption, Boosts Pacira's Non-Opioid Push
Event summary
- A survey of 750 hospital and ASC directors found 85% were aware of the NOPAIN Act.
- 52% of facilities surveyed have taken steps to increase the use of non-opioid pain management options.
- 83% of respondents reported decreased opioid prescribing immediately after surgery, and 88% at discharge.
- The NOPAIN Act went into effect on January 1, 2025, as part of the Consolidated Appropriations Act of 2023.
The big picture
The NOPAIN Act represents a significant shift in pain management practices, driven by mounting pressure to address the opioid crisis. Pacira, as a leading provider of non-opioid alternatives, is positioned to benefit from this regulatory tailwind, but its success hinges on broader adoption across the healthcare system and sustained clinical efficacy.
What we're watching
- Commercial Adoption
- While Medicare adoption is evident, the pace at which commercial payers follow suit will be critical for Pacira's long-term revenue growth and market penetration.
- Protocol Shifts
- The sustainability of the reported protocol changes within hospitals and ASCs will depend on ongoing education, reimbursement models, and potential resistance from surgeons or anesthesiologists.
- Competitive Landscape
- How other non-opioid pain management companies respond to the NOPAIN Act and Pacira's market position will shape the competitive dynamics within the sector.
Related topics